All In Biotech

Drug Trial Radar · NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 11,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11,000

Actual

Start

Mar 15, 2018

Primary completion

Jul 24, 2021

Study completion Oct 29, 2021

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Dec 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized placebo-controlled trial of 11,000 women to assess whether tranexamic acid as prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a cesarean delivery.

Conditions

  • Obstetrical Complications
  • Hemorrhage
  • Labor and Delivery

Interventions

  • Tranexamic AcidDrug

    A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)

  • PlaceboDrug

    50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Maternal Death or Transfusion of Packed Red Blood CellsTime frame: by hospital discharge or by 7 days postpartum, whichever is sooner

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Northwestern University-Prentice Hospital

    Chicago, Illinois

  • Columbia University

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Case Western Reserve-MetroHealth

    Cleveland, Ohio

  • Ohio State University Hospital

    Columbus, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Magee Women's Hospital of UPMC

    Pittsburgh, Pennsylvania

  • Brown University

    Providence, Rhode Island

  • University of Texas Medical Branch

    Galveston, Texas

  • University of Texas - Houston

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.